Anika Therapeutics financials
$19.95−3.55%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M | $113.8M | $147.8M | $130.5M | $114.6M | $105.6M | $113.4M | $103.4M |
| Gross profit | $63.8M | $76.0M | $82.5M | $73.2M | $82.9M | $69.0M | $85.9M | $74.3M | $86.1M | $79.4M |
| Gross margin | 56.6% | 63.4% | 68.3% | 64.3% | 56.1% | 52.9% | 74.9% | 70.4% | 75.9% | 76.8% |
| Operating income | -$11.1M | -$5.1M | $844.0K | $3.7M | $2.6M | -$28.3M | $34.2M | $21.7M | $45.7M | $50.6M |
| Net income | -$10.9M | -$56.4M | -$82.7M | -$14.9M | $4.1M | -$24.0M | $27.2M | $18.7M | $31.8M | $32.5M |
| Net margin | −9.6% | −47.0% | −68.4% | −13.1% | 2.8% | −18.4% | 23.7% | 17.7% | 28.1% | 31.5% |
| Diluted EPS | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 | $-1.69 | $1.89 | $1.27 | $2.11 | $2.15 |
| EBITDA | -$5.3M | $3.0M | $15.1M | $18.2M | -$2.5M | $2.7M | $39.2M | $27.7M | $50.0M | $54.3M |
| Operating cash flow | $11.2M | $5.4M | -$1.8M | $4.4M | $29.5M | -$6.9M | $37.0M | $34.9M | $40.8M | $24.4M |
| Free cash flow | $4.4M | -$2.3M | -$7.2M | -$3.1M | $24.3M | -$8.6M | $34.2M | $30.3M | $31.8M | $10.4M |
| Diluted shares | 14.3M | 14.7M | 14.7M | 14.8M | 14.6M | 14.2M | 14.4M | 14.7M | 15.1M | 15.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $57.5M | $55.6M | $68.7M | $86.3M | $94.4M | $95.8M |
| Short-term investments | $0.00 | $23.6M | $26.4M | $34.6M | $29.8M | $2.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $190.3M | $202.7M | $270.6M | $349.1M | $347.5M | $365.6M |
| Total liabilities | $46.8M | $48.8M | $58.4M | $63.6M | $60.5M | $93.2M |
| Shareholders' equity | $143.5M | $154.0M | $212.3M | $285.6M | $287.1M | $272.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology